An international analysis published in Circulation and a new scientific statement from the American Heart Association both explore the latest data on heart complications associated with COVID-19. 

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.

Drug-coated balloons were associated with a lower risk of bleeding after PCI than drug-eluting stents, the study's authors reported. 

Mass General cardiologist and Harvard professor Ami Bhatt, MD, predicts upcoming paradigm shifts in cardiology over the next decade. 

The study's authors examined data from the DANAMI-3 trial, focusing on such outcomes as all-cause mortality, recurrent MI and target vessel revascularization.

The new algorithm was designed to evaluate a user's heart rhythm while they are still or even sleeping.